ORIGINAL RESEARCH article
Front. Med.
Sec. Gastroenterology
This article is part of the Research TopicHost-Microbiota Interactions in IBD: Immune Modulation and Barrier FunctionView all 4 articles
Association Study between Intestinal Microbiota Dysbiosis in Inflammatory Bowel Disease and the Global Disease Burden Growth Trend
Provisionally accepted
- Jinjiang Municipal Hospital, Quanzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is a group of chronic intestinal inflammatory diseases. Its incidence and prevalence have been on the rise globally, imposing a heavy burden on patients' health and social medical resources.By searching the Global Burden of Disease (GBD) study database, we collected IBD disease burden data from 180 countries and regions between 1990 and 2023, including key indicators such as incidence, prevalence, mortality, and disability - adjusted life years (DALYs). Intestinal microbiota data were sourced from two parts: 1) Independent collection: A total of 20,000 healthy individuals and IBD patients were selected as research subjects from 180 countries and regions using a stratified random sampling method. Fecal samples (2-5 grams per person) were collected and immediately stored in a -80°C ultra-low temperature refrigerator to avoid changes in the microbial community structure; 2) Supplementary data from public databases: Published intestinal microbiota sequencing data of corresponding regions from 1990 to 2023 were extracted from the MGnify (https://www.ebi.ac.uk/metagenomics/), Human Microbiome Project (HMP), and GMrepo (https://gmrepo.humangut.info/) databases.The global incidence of IBD increased from 12.3 per 100,000 in 1990 to 25.6 per 100,000 in 2023, the prevalence rose from 396 per 100,000 to 523 per 100,000, and the DALY value also increased significantly (from 230 per 100,000 in 1990 to 380 per 100,000 in 2023). The average annual growth rates of the above indicators were 2.8% (95%CI: 2.5%-3.1%, P<0.001), 1.0% (95%CI: 0.8%-1.2%, P<0.001), and 1.5% (95%CI: 1.3%-1.7%, P<0.001), respectively. Further analysis showed that intestinal microbiota dysbiosis was closely related to the growth of the disease burden.In regions with severe microbiota dysbiosis, the annual growth rate of the IBD incidence was 3.2 times higher than that in balanced regions (β=3.2, 95%CI: 2.8-3.6, P<0.001).This study confirms a close association between intestinal microbiota dysbiosis in inflammatory bowel disease and the global disease burden growth trend. Intestinal microbiota dysbiosis can be used as a key indicator to predict the growth of the IBD disease burden, providing an important theoretical basis for formulating targeted prevention, control strategies, and treatment methods.
Keywords: inflammatory bowel disease, Intestinal microbiota dysbiosis, Global disease burden, Incidence, Prevalence, Disability - adjusted life years
Received: 26 May 2025; Accepted: 10 Nov 2025.
Copyright: © 2025 Li, Guo, Shi, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Longqin Li, jjsyyxhnk@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.